Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 1/2018

01-02-2018 | Original Article

Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients

Authors: Niveditha Muralidharan, Reena Gulati, Durga Prasanna Misra, Vir S. Negi

Published in: Clinical and Experimental Medicine | Issue 1/2018

Login to get access

Abstract

The aim of the study was to look for any association of MTR 2756A>G and MTRR 66A>G gene polymorphisms with clinical phenotype, methotrexate (MTX) treatment response, and MTX-induced adverse events in South Indian Tamil patients with rheumatoid arthritis (RA). A total of 335 patients with RA were investigated. MTR 2756A>G gene polymorphism was analyzed by PCR–RFLP, and MTRR 66A>G SNP was analyzed by TaqMan 5′ nuclease assay. The allele frequencies were compared with HapMap groups. MTR 2756G allele was found to be associated with risk of developing RA. The allele frequencies of MTR 2756A>G and MTRR 66A>G SNPs in controls differed significantly when compared with HapMap groups. Neither of the SNPs influenced the MTX treatment outcome and adverse effects. Neither of the SNPs seems to be associated with MTX treatment outcome and adverse events in South Indian Tamil patients with RA.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Tobón GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev. 2010;9:A288–92.CrossRefPubMed
4.
5.
6.
7.
Colmegna I, Ohata BR, Menard HA. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther. 2012;91:607–20.CrossRefPubMed
8.
Wesoly J, Wessels JAM, Guchelaar H-J, Huizinga TWJ. Genetic markers of treatment response in rheumatoid arthritis. Curr Rheumatol Rep. 2006;8:369–77.CrossRefPubMed
9.
Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 2006;54:1366–77.CrossRefPubMed
10.
Burgos PI, Danila MI, Kelley JM, Hughes LB, Bridges SL. Understanding personalized medicine in rheumatoid arthritis: a clinician’s guide to the future. Ther Adv Musculoskelet Dis. 2009;1:97–105.CrossRefPubMedPubMedCentral
11.
Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatol Oxf Engl. 2007;46:1520–4.CrossRef
12.
Spyridopoulou KP, Dimou NL, Hamodrakas SJ, Bagos PG. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis. Pharmacogenet Genomics. 2012;22:117–33.CrossRefPubMed
13.
Owen SA, Lunt M, Bowes J, Hider SL, Bruce IN, Thomson W, et al. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J. 2013;13:137–47.CrossRefPubMed
14.
Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol. 2008;64:1057–68.CrossRefPubMed
15.
Wessels JAM, Kooloos WM, De Jonge R, De Vries-Bouwstra JK, Allaart CF, Linssen A, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006;54:2830–9.CrossRefPubMed
16.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.CrossRefPubMed
17.
Van Gestel AM, Prevoo ML, van’t Hof MA, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34–40.CrossRefPubMed
18.
19.
Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR, et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood. 2002;99:3786–91.CrossRefPubMed
20.
Waseem M, Hussain SR, Kumar S, Serajuddin M, Mahdi F, Sonkar SK, et al. Association of MTHFR (C677T) gene polymorphism with breast cancer in North India. Biomark Cancer. 2016;8:111–7.CrossRefPubMedPubMedCentral
21.
Nikbakht M, MalekZadeh K, Kumar Jha A, Askari M, Marwaha RK, Kaul D, et al. Polymorphisms of MTHFR and MTR genes are not related to susceptibility to childhood ALL in North India. Exp Oncol. 2012;34:43–8.PubMed
22.
Zhang Z, Shi Q, Liu Z, Sturgis EM, Spitz MR, Wei Q. Polymorphisms of methionine synthase and methionine synthase reductase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Cancer Epidemiol Biomark Prev. 2005;14:1188–93.CrossRef
23.
Yu K, Zhang J, Zhang J, Dou C, Gu S, Xie Y, et al. Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet EJHG. 2010;18:370–8.CrossRefPubMed
24.
Van der Put NM, van der Molen EF, Kluijtmans LA, Heil SG, Trijbels JM, Eskes TK, et al. Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease. QJM Mon J Assoc Physicians. 1997;90:511–7.CrossRef
25.
Yates Z, Lucock M. Methionine synthase polymorphism A2756G is associated with susceptibility for thromboembolic events and altered B vitamin/thiol metabolism. Haematologica. 2002;87:751–6 (discussion 756).PubMed
26.
Mir MM, Dar JA, Dar NA, Dar MS, Salam I, Lone MM, et al. Combined impact of polymorphism of folate metabolism genes; glutamate carboxypeptidase, methylene tetrahydrofolate reductase and methionine synthase reductase on breast cancer susceptibility in kashmiri women. Int J Health Sci. 2008;2:3–14.
27.
Rai V, Yadav U, Kumar P. MTRR A66G polymorphism among two caste groups of Uttar Pradesh (India). Indian J Med Sci. 2012;66:136–40.CrossRefPubMed
28.
Kim DJ, Park BL, Koh J-M, Kim GS, Kim LH, Cheong HS, et al. Methionine synthase reductase polymorphisms are associated with serum osteocalcin levels in postmenopausal women. Exp Mol Med. 2006;38:519–24.CrossRefPubMed
29.
Naushad SM, Jain Jamal MN, Prasad CK, Rama Devi AR. Relationship between methionine synthase, methionine synthase reductase genetic polymorphisms and deep vein thrombosis among South Indians. Clin Chem Lab Med. 2008;46:73–9.CrossRefPubMed
30.
Hu S, Liu H-C, Xi S-M. Methionine synthase reductase A66G polymorphism is not associated with breast cancer susceptibility—a meta-analysis. Asian Pac J Cancer Prev APJCP. 2014;15:3267–71.CrossRefPubMed
31.
Miriuka SG, Langman LJ, Evrovski J, Miner SES, D’Mello N, Delgado DH, et al. Genetic polymorphisms predisposing to hyperhomocysteinemia in cardiac transplant patients. Transpl Int Off J Eur Soc Organ Transplant. 2005;18:29–35.CrossRef
32.
Silaste ML, Rantala M, Sämpi M, Alfthan G, Aro A, Kesäniemi YA. Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. J Nutr. 2001;131:2643–7.CrossRefPubMed
33.
James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol. 2008;35:562–71.PubMed
34.
Berkun Y, Abou Atta I, Rubinow A, Orbach H, Levartovsky D, Aamar S, et al. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis. J Rheumatol. 2007;34:1664–9.PubMed
35.
Ghodke Y, Chopra A, Shintre P, Puranik A, Joshi K, Patwardhan B. Profiling single nucleotide polymorphisms (SNPs) across intracellular folate metabolic pathway in healthy Indians. Indian J Med Res. 2011;133:274–9.PubMedPubMedCentral
36.
Rai PS, Murali TS, Vasudevan TG, Prasada SK, Bhagavath AK, Pai P, et al. Genetic variation in genes involved in folate and drug metabolism in a south Indian population. Indian J Hum Genet. 2011;17(Suppl 1):S48–53.CrossRefPubMedPubMedCentral
37.
Burzynski M, Duriagin S, Mostowska M, Wudarski M, Chwalinska-Sadowska H, Jagodzinski PP. MTR 2756 A>G polymorphism is associated with the risk of systemic lupus erythematosus in the Polish population. Lupus. 2007;16:450–4.CrossRefPubMed
38.
Rincón JFM, Cano DL, Morales SJ, Jiménez MLR, Cobos REB, Bello JR. The functional PTPN22 C1858T polymorphism confers risk for rheumatoid arthritis in patients from Central Mexico. Clin Rheumatol. 2016;35:1457–62.CrossRefPubMed
39.
Raslan HM, Attia HR, Salama I, Ibrahim MH, Hassan EM, El Hussieny MS, et al. Association of PTPN22 1858C → T polymorphism, HLA-DRB1 shared epitope and autoantibodies with rheumatoid arthritis. Rheumatol Int. 2016;36:1167–75.CrossRefPubMed
40.
Chen Y, Dawes PT, Packham JC, Mattey DL. Interaction between smoking and functional polymorphism in the TGFB1 gene is associated with ischaemic heart disease and myocardial infarction in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2012;14:R81.CrossRefPubMedPubMedCentral
41.
Chaabane S, Marzouk S, Akrout R, Ben Hamad M, Achour Y, Rebai A, et al. Genetic determinants of methotrexate toxicity in tunisian patients with rheumatoid arthritis: a study of polymorphisms involved in the MTX metabolic pathway. Eur J Drug Metab Pharmacokinet. 2016;41:385–93.CrossRefPubMed
42.
Stamp LK, Chapman PT, O’Donnell JL, Zhang M, James J, Frampton C, et al. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet Genomics. 2010;20:367–76.CrossRefPubMed
43.
Wessels JAM, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007;56:1765–75.CrossRefPubMed
Metadata
Title
Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients
Authors
Niveditha Muralidharan
Reena Gulati
Durga Prasanna Misra
Vir S. Negi
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 1/2018
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-017-0469-y

Other articles of this Issue 1/2018

Clinical and Experimental Medicine 1/2018 Go to the issue

Original Article

Circulating fibroblast growth factor 21 in patients with liver cirrhosis

Original Article

Assessing liver proteins and enzymes of medical workers exposed to ionizing radiation (IR)

Letter to the Editor

Association between telomere length and PIK3CA amplification in gastric cancer

Original Article

SATB2 suppresses non-small cell lung cancer invasiveness by G9a

Original Article

Age-related alterations of the CD19 complex and memory B cells in children with Down syndrome

Original Article

Association of serum bilirubin with oxidant damage of human atherosclerotic plaques and the severity of atherosclerosis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits